Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.41 |
| ▸ | HTR2B | P41595 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23161482 | 0.79 | PDE3B (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3516499 | 0.76 | HTR2C (0.39) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL18953822 | 0.73 | CPB2 (0.40) | HTR2CADORA2AADORA1CPB2 | |
| SCHEMBL13266064 | 0.69 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL13506399 | 0.68 | MEN1 (0.39) | ADORA2A | |
| SCHEMBL11517664 | 0.67 | HTR2A (0.31) | HTR2CHTR2A | |
| SCHEMBL11485113 | 0.67 | HTR2A (0.31) | HTR2CHTR2A | |
| SCHEMBL8819204 | 0.67 | HRH3 (0.34) | HTR2CHTR2BHTR2A | |
| SCHEMBL11500204 | 0.67 | ADORA2B (0.33) | — | |
| SCHEMBL11501250 | 0.67 | ADORA2B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134723-B1 | 2,6 DIAMINO-9H-PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-8404674-B2 | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20100311721-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311721-A1 | COMPOUNDS | CCNA1, MKI67, CCNT1 | HTR2C 2726/4885HTR2B 2930/4885HTR2A 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.